Pharmaceutical Crystals. / Volume II / / Etsuo Yonemochi, Hidehiro Uekusa, editor.

The crystalline state is the most commonly used as an essential solid in active pharmaceutical ingredients (API). The characterization of pharmaceutical crystals encompasses many scientific disciplines. Still, the core is crystal structure analysis, which reveals the molecular structure of essential...

Full description

Saved in:
Bibliographic Details
TeilnehmendeR:
Place / Publishing House:Basel : : MDPI - Multidisciplinary Digital Publishing Institute,, 2023.
Year of Publication:2023
Language:English
Physical Description:1 online resource (176 pages)
Tags: Add Tag
No Tags, Be the first to tag this record!
id 993599253104498
ctrlnum (CKB)5700000000354315
(NjHacI)995700000000354315
(EXLCZ)995700000000354315
collection bib_alma
record_format marc
spelling Pharmaceutical Crystals. Volume II / Etsuo Yonemochi, Hidehiro Uekusa, editor.
Pharmaceutical Crystals
Basel : MDPI - Multidisciplinary Digital Publishing Institute, 2023.
1 online resource (176 pages)
text txt rdacontent
computer c rdamedia
online resource cr rdacarrier
Description based on publisher supplied metadata and other sources.
The crystalline state is the most commonly used as an essential solid in active pharmaceutical ingredients (API). The characterization of pharmaceutical crystals encompasses many scientific disciplines. Still, the core is crystal structure analysis, which reveals the molecular structure of essential pharmaceutical compounds. Crystal structure analysis provides important structural information related to the API's wide range of physicochemical properties, such as solubility, stability, tablet performance, color, and hygroscopicity. These properties should be understood in terms of molecular structures and interactions between molecules in crystals. Information on three-dimensional molecular structures also affords insights into the biological activity of molecules. The second reprint in the series, "Crystalline Pharmaceuticals (Volume II)" focused on the relationship between crystal structure and physicochemical properties. In particular, the new crystal structure of pharmaceutical compounds involving multi-component crystals, such as co-crystals, salts and hydrates, and polymorph crystals, were reported with interest. Such crystal structures contributed to the latest studies that combine morphology, spectroscopic, theoretical calculation, and thermal analysis with the crystallographic study. Thus, this reprint highlights the importance of crystal structure information in many areas of pharmaceutical science and presents current trends in the structure-property study of pharmaceutical crystals. The Guest Editors of this reprint hope the readers enjoy a wide variety of recent studies on "Crystalline Pharmaceuticals."
Pharmaceutical chemistry.
3-0365-5473-4
Uekusa, Hidehiro, editor.
Yonemochi, Etsuo, editor.
language English
format eBook
author2 Uekusa, Hidehiro,
Yonemochi, Etsuo,
author_facet Uekusa, Hidehiro,
Yonemochi, Etsuo,
author2_variant h u hu
e y ey
author2_role TeilnehmendeR
TeilnehmendeR
title Pharmaceutical Crystals.
spellingShingle Pharmaceutical Crystals.
title_full Pharmaceutical Crystals. Volume II / Etsuo Yonemochi, Hidehiro Uekusa, editor.
title_fullStr Pharmaceutical Crystals. Volume II / Etsuo Yonemochi, Hidehiro Uekusa, editor.
title_full_unstemmed Pharmaceutical Crystals. Volume II / Etsuo Yonemochi, Hidehiro Uekusa, editor.
title_auth Pharmaceutical Crystals.
title_alt Pharmaceutical Crystals
title_new Pharmaceutical Crystals.
title_sort pharmaceutical crystals.
publisher MDPI - Multidisciplinary Digital Publishing Institute,
publishDate 2023
physical 1 online resource (176 pages)
isbn 3-0365-5474-2
3-0365-5473-4
callnumber-first Q - Science
callnumber-subject QD - Chemistry
callnumber-label QD921
callnumber-sort QD 3921 P437 42023
illustrated Not Illustrated
dewey-hundreds 500 - Science
dewey-tens 540 - Chemistry
dewey-ones 548 - Crystallography
dewey-full 548
dewey-sort 3548
dewey-raw 548
dewey-search 548
work_keys_str_mv AT uekusahidehiro pharmaceuticalcrystalsvolumeii
AT yonemochietsuo pharmaceuticalcrystalsvolumeii
AT uekusahidehiro pharmaceuticalcrystals
AT yonemochietsuo pharmaceuticalcrystals
status_str n
ids_txt_mv (CKB)5700000000354315
(NjHacI)995700000000354315
(EXLCZ)995700000000354315
carrierType_str_mv cr
is_hierarchy_title Pharmaceutical Crystals.
author2_original_writing_str_mv noLinkedField
noLinkedField
_version_ 1796653152476332032
fullrecord <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>02638nam a2200301 i 4500</leader><controlfield tag="001">993599253104498</controlfield><controlfield tag="005">20230704093135.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr |||||||||||</controlfield><controlfield tag="008">230704s2023 sz o 000 0 eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">3-0365-5474-2</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(CKB)5700000000354315</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(NjHacI)995700000000354315</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(EXLCZ)995700000000354315</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">NjHacI</subfield><subfield code="b">eng</subfield><subfield code="e">rda</subfield><subfield code="c">NjHacl</subfield></datafield><datafield tag="050" ind1=" " ind2="4"><subfield code="a">QD921</subfield><subfield code="b">.P437 2023</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">548</subfield><subfield code="2">23</subfield></datafield><datafield tag="245" ind1="0" ind2="0"><subfield code="a">Pharmaceutical Crystals.</subfield><subfield code="n">Volume II /</subfield><subfield code="c">Etsuo Yonemochi, Hidehiro Uekusa, editor.</subfield></datafield><datafield tag="246" ind1=" " ind2=" "><subfield code="a">Pharmaceutical Crystals </subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Basel :</subfield><subfield code="b">MDPI - Multidisciplinary Digital Publishing Institute,</subfield><subfield code="c">2023.</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 online resource (176 pages)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="588" ind1=" " ind2=" "><subfield code="a">Description based on publisher supplied metadata and other sources.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The crystalline state is the most commonly used as an essential solid in active pharmaceutical ingredients (API). The characterization of pharmaceutical crystals encompasses many scientific disciplines. Still, the core is crystal structure analysis, which reveals the molecular structure of essential pharmaceutical compounds. Crystal structure analysis provides important structural information related to the API's wide range of physicochemical properties, such as solubility, stability, tablet performance, color, and hygroscopicity. These properties should be understood in terms of molecular structures and interactions between molecules in crystals. Information on three-dimensional molecular structures also affords insights into the biological activity of molecules. The second reprint in the series, "Crystalline Pharmaceuticals (Volume II)" focused on the relationship between crystal structure and physicochemical properties. In particular, the new crystal structure of pharmaceutical compounds involving multi-component crystals, such as co-crystals, salts and hydrates, and polymorph crystals, were reported with interest. Such crystal structures contributed to the latest studies that combine morphology, spectroscopic, theoretical calculation, and thermal analysis with the crystallographic study. Thus, this reprint highlights the importance of crystal structure information in many areas of pharmaceutical science and presents current trends in the structure-property study of pharmaceutical crystals. The Guest Editors of this reprint hope the readers enjoy a wide variety of recent studies on "Crystalline Pharmaceuticals."</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Pharmaceutical chemistry.</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">3-0365-5473-4</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Uekusa, Hidehiro,</subfield><subfield code="e">editor.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Yonemochi, Etsuo,</subfield><subfield code="e">editor.</subfield></datafield><datafield tag="906" ind1=" " ind2=" "><subfield code="a">BOOK</subfield></datafield><datafield tag="ADM" ind1=" " ind2=" "><subfield code="b">2023-07-08 12:20:33 Europe/Vienna</subfield><subfield code="f">system</subfield><subfield code="c">marc21</subfield><subfield code="a">2023-04-02 14:12:45 Europe/Vienna</subfield><subfield code="g">false</subfield></datafield><datafield tag="AVE" ind1=" " ind2=" "><subfield code="i">DOAB Directory of Open Access Books</subfield><subfield code="P">DOAB Directory of Open Access Books</subfield><subfield code="x">https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&amp;portfolio_pid=5345554460004498&amp;Force_direct=true</subfield><subfield code="Z">5345554460004498</subfield><subfield code="b">Available</subfield><subfield code="8">5345554460004498</subfield></datafield><datafield tag="AVE" ind1=" " ind2=" "><subfield code="i">DOAB Directory of Open Access Books</subfield><subfield code="P">DOAB Directory of Open Access Books</subfield><subfield code="x">https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&amp;portfolio_pid=5345668830004498&amp;Force_direct=true</subfield><subfield code="Z">5345668830004498</subfield><subfield code="b">Available</subfield><subfield code="8">5345668830004498</subfield></datafield></record></collection>